REFERENCES
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
2. Hong TP, Gow P, Fink M, et al. Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed. Hepatology. 2016;63:1205-12.
3. Huang DQ, Terrault NA, Tacke F, et al. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023;20:388-98.
4. Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236.
5. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723-50.
6. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-70.
7. Lubel JS, Roberts SK, Strasser SI, et al. Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. Med J Aust. 2021;214:475-83.
8. Hong TP, Gow PJ, Fink M, et al. Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study. Med J Aust. 2018;209:348-54.
9. Singal AG, Zhang E, Narasimman M, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;77:128-39.
10. Hui S, Bell S, Le S, Dev A. Hepatocellular carcinoma surveillance in Australia: current and future perspectives. Med J Aust. 2023;219:432-8.
11. Parikh ND, Tayob N, Singal AG. Blood-based biomarkers for hepatocellular carcinoma screening: approaching the end of the ultrasound era? J Hepatol. 2023;78:207-16.
12. Liebman HA, Furie BC, Tong MJ, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310:1427-31.
13. Taketa K, Endo Y, Sekiya C, et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res. 1993;53:5419-23.
14. Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: a systematic review. Hepatol Res. 2014;44:E11-25.
15. Piratvisuth T, Hou J, Tanwandee T, et al. Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies. Hepatol Commun. 2023;7:e0317.
16. Parikh ND, Singal AG, Hutton DW, Tapper EB. Cost-effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms. Am J Gastroenterol. 2020;115:1642-9.
17. Nguyen ALT, Si L, Lubel JS, et al. Hepatocellular carcinoma surveillance based on the Australian Consensus Guidelines: a health economic modelling study. BMC Health Serv Res. 2023;23:378.
18. Nan Y, Garay OU, Lu X, et al. Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost-effectiveness analysis. J Comp Eff Res. 2024;13:e230146.
19. Singal AG, Chhatwal J, Parikh N, Tapper E. Cost-effectiveness of a biomarker-based screening strategy for hepatocellular carcinoma in patients with cirrhosis. Liver Cancer. 2024;13:643-54.
20. Husereau D, Drummond M, Petrou S, et al; CHEERS Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013;346:f1049.
21. Australian Bureau of Statistics. Provisional Mortality Statistics. Available from: https://www.abs.gov.au/statistics/health/causes-death/provisional-mortality-statistics/latest-release. [Last accessed on 5 Sep 2025].
22. Department of Health and Aged Care Australian Government. MBS Online. Available from: https://www.mbsonline.gov.au/. [Last accessed on 5 Sep 2025].
23. Department of Health and Aged Care Australian Government. Pharmaceutical Benefits Scheme (PBS). Available from: https://www.pbs.gov.au/pbs/home. [Last accessed on 5 Sep 2025].
24. Zhao C, Jin M, Le RH, et al. Poor adherence to hepatocellular carcinoma surveillance: a systematic review and meta-analysis of a complex issue. Liver Int. 2018;38:503-14.
25. Low ES, Apostolov R, Wong D, et al. Hepatocellular carcinoma surveillance and quantile regression for determinants of underutilisation in at-risk Australian patients. World J Gastrointest Oncol. 2021;13:2149-60.
26. Hui S, Sane N, Wang A, et al. Hepatocellular carcinoma surveillance in the telehealth era: a single-centre review. J Telemed Telecare. 2025;31:64-72.
27. Allard N, Cabrie T, Wheeler E, et al. The challenge of liver cancer surveillance in general practice: do recall and reminder systems hold the answer? Aust Fam Physician. 2017;46:859-64.
28. Coombs PR, Chen J, Curry GJ, et al. Sonography in a large Australian public ultrasound service: 10 years of change and innovation. Sonography. 2024;11:169-76.
